Učitavanje...
PI3K Inhibitors: Present and Future
Inhibitors of PI3Kδ hold great potential for the therapy of CLL and B cell malignancies. After initially exciting efficacy results with idelalisib, the first in class inhibitor, the emergence of unexpected and unpredictable autoimmune toxicities, worse in less heavily treated and younger patients, h...
Spremljeno u:
| Izdano u: | Cancer J |
|---|---|
| Glavni autor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7082729/ https://ncbi.nlm.nih.gov/pubmed/31764120 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0000000000000414 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|